The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

By Karen Roman

VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund.

The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) and to advance its cancer therapies pipeline, VERAXA stated.

“Securing these financings marks a significant step in our ongoing business combination with Voyager Acquisition Corp. and the expected listing of VERAXA shares on NASDAQ,” said Torsten Bürgermeister, VERAXA’s CFO. “We appreciate the financial support of these investors as we continue to employ a disciplined approach to balance sheet management through efficient and flexible access to capital.”d

READ MORE

Never Miss our Weekly Highlights HERE

Contact:

Exec Edge

Editor@executives-edge.com

Click HERE to follow us on LinkedIn